Published in Neuropsychopharmacology on May 09, 2007
Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 11.25
Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry (2009) 3.24
From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology (2011) 2.70
Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology (2010) 2.20
Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr Top Med Chem (2013) 1.28
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull (2007) 1.21
The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav (2010) 1.16
Activation of corticostriatal circuitry relieves chronic neuropathic pain. J Neurosci (2015) 1.05
Zebrafish: An in vivo model for the study of neurological diseases. Neuropsychiatr Dis Treat (2008) 1.01
Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry (2013) 1.00
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull (2011) 0.97
Challenges for and current status of research into positive modulators of AMPA receptors. Br J Pharmacol (2010) 0.95
Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches. Psychiatr Clin North Am (2012) 0.95
The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry (2014) 0.93
Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Mol Psychiatry (2015) 0.93
Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. Psychopharmacology (Berl) (2008) 0.92
Postmortem brain: an underutilized substrate for studying severe mental illness. Neuropsychopharmacology (2013) 0.91
Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur Neuropsychopharmacol (2008) 0.90
Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Mol Psychiatry (2015) 0.90
Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat (2011) 0.89
The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases. Exp Neurol (2008) 0.89
Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl) (2009) 0.88
Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berl) (2008) 0.87
Beyond dopamine: glutamate as a target for future antipsychotics. ISRN Pharmacol (2012) 0.86
Growth hormone and insulin-like growth factor-I alter hippocampal excitatory synaptic transmission in young and old rats. Age (Dordr) (2012) 0.85
Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front Psychiatry (2014) 0.85
A quantitative system pharmacology computer model for cognitive deficits in schizophrenia. CPT Pharmacometrics Syst Pharmacol (2013) 0.83
Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. Psychopharmacology (Berl) (2008) 0.80
Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576. Psychopharmacology (Berl) (2011) 0.80
Development of antipsychotic medications with novel mechanisms of action based on computational modeling of hippocampal neuropathology. PLoS One (2013) 0.80
Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments. Biomol Ther (Seoul) (2012) 0.80
Genetic Approaches to Understanding Psychiatric Disease. Neurotherapeutics (2017) 0.80
Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research. Br J Pharmacol (2017) 0.79
The neuropharmacology of implicit learning. Curr Neuropharmacol (2010) 0.79
Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia. Curr Pharm Biotechnol (2012) 0.77
Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission. Psychopharmacology (Berl) (2011) 0.76
Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. Int J Mol Sci (2017) 0.75
Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator. Br J Pharmacol (2017) 0.75
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
A synaptic model of memory: long-term potentiation in the hippocampus. Nature (1993) 29.13
AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci (2002) 13.09
A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl (1970) 10.05
Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull (2000) 9.62
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
A rating scale for drug-induced akathisia. Br J Psychiatry (1989) 7.30
The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull (1984) 5.69
Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry (2006) 5.30
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell (1999) 4.93
Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry (2006) 4.77
A depression rating scale for schizophrenics. Schizophr Res (1991) 3.70
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry (2001) 3.20
Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res (1988) 2.68
Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry (1997) 2.48
SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull (1986) 2.46
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress. Schizophr Bull (1992) 2.08
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull (1999) 1.99
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry (2004) 1.58
Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine. Mol Psychiatry (1996) 1.45
Neuropharmacology of AMPA and kainate receptors. Neuropharmacology (1999) 1.43
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry (2005) 1.34
Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci U S A (1994) 1.33
Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl) (2005) 1.29
Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev (2000) 1.29
AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord (2004) 1.28
Enhancement by an ampakine of memory encoding in humans. Exp Neurol (1997) 1.24
Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action. J Pharmacol Exp Ther (2002) 1.14
Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther (1999) 1.14
Chronic elevation of brain-derived neurotrophic factor by ampakines. J Pharmacol Exp Ther (2003) 1.12
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol (2001) 1.08
Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Proc Natl Acad Sci U S A (1994) 1.07
Molecular mechanisms associated with long-term consolidation of the NMDA signals. Life Sci (2000) 1.05
Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol (1997) 1.05
A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry (1999) 1.00
Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci (1998) 0.98
D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry (1999) 0.95
Effects of a centrally active benzoylpyrrolidine drug on AMPA receptor kinetics. Neuroscience (1996) 0.94
AMPA receptor desensitization modulates synaptic responses induced by repetitive afferent stimulation in hippocampal slices. Brain Res (1998) 0.93
Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus. J Pharmacol Exp Ther (1996) 0.93
Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors. Mol Pharmacol (1995) 0.92
A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse (1993) 0.90
Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry (2001) 0.90
Facilitation of olfactory learning by a modulator of AMPA receptors. J Neurosci (1995) 0.90
Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse (1999) 0.88
Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry (2000) 0.84
Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry (1999) 0.84
Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res (2002) 0.82
Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression. Synapse (1998) 0.82
AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired. J Neurosci (1997) 0.82
The waveform of synaptic transmission at hippocampal synapses is not determined by AMPA receptor desensitization. Brain Res (1998) 0.82
Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion. Eur J Pharmacol (1997) 0.82
AMPA receptor modulators have different impact on hippocampal pyramidal cells and interneurons. Neuroscience (2005) 0.82
Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum. Brain Res Mol Brain Res (1997) 0.82
Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther (1999) 0.80
Psychological effects of a drug that facilitates brain AMPA receptors. Int Clin Psychopharmacol (1996) 0.79
Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain. Eur J Pharmacol (1996) 0.79
Effects of chronic haloperidol and clozapine treatment on AMPA and kainate receptor binding in rat brain. Pharmacopsychiatry (2003) 0.79
Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate. Neuroscience (2000) 0.77
The NimStim set of facial expressions: judgments from untrained research participants. Psychiatry Res (2009) 11.53
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry (2002) 6.99
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Identification of separable cognitive factors in schizophrenia. Schizophr Res (2004) 5.34
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull (2005) 4.66
Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction (2003) 4.25
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res (2007) 3.79
A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry (2003) 3.59
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Suicide among New York City police officers, 1977-1996. Am J Psychiatry (2002) 3.51
Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry (2007) 2.91
Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry (2013) 2.80
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Biosocial pathways to functional outcome in schizophrenia. Schizophr Res (2005) 2.65
Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr Bull (2006) 2.53
Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry (2007) 2.43
Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. Am J Psychiatry (2006) 2.42
Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry (2005) 2.32
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry (2006) 2.31
Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry (2013) 2.24
Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry (2010) 2.18
Nonconscious and conscious color priming in schizophrenia. J Psychiatr Res (2012) 2.08
A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol (2005) 2.07
Income distribution and risk of fatal drug overdose in New York City neighborhoods. Drug Alcohol Depend (2003) 2.01
Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv (2007) 1.99
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
A randomized controlled clinical trial of psychoanalytic psychotherapy for panic disorder. Am J Psychiatry (2007) 1.93
Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2011) 1.93
Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry (2005) 1.91
Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia. Bipolar Disord (2009) 1.90
Is emotion processing a predictor of functional outcome in schizophrenia? Schizophr Bull (2003) 1.89
The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull (2006) 1.88
Affective traits in schizophrenia and schizotypy. Schizophr Bull (2008) 1.81
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res (2006) 1.80
Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull (2006) 1.75
Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry (2004) 1.75
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol Psychiatry (2004) 1.72
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull (2007) 1.72
Does anhedonia in schizophrenia reflect faulty memory for subjectively experienced emotions? J Abnorm Psychol (2006) 1.71
From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch Gen Psychiatry (2012) 1.68
Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res (2006) 1.67
Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry (2005) 1.67
The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology (2007) 1.67
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol (2007) 1.66
Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry (2004) 1.65
The long-term course of rapid-cycling bipolar disorder. Arch Gen Psychiatry (2003) 1.63
A quality-based review of randomized controlled trials of psychodynamic psychotherapy. Am J Psychiatry (2010) 1.62
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry (2005) 1.61
The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res (2004) 1.59
Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry (2003) 1.56
Social cognition in schizophrenia, Part 2: 12-month stability and prediction of functional outcome in first-episode patients. Schizophr Bull (2011) 1.56
Determining when impairment constitutes incapacity for informed consent in schizophrenia research. Br J Psychiatry (2007) 1.56
How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr Bull (2007) 1.53
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
Social cognition in psychosis: multidimensional structure, clinical correlates, and relationship with functional outcome. Schizophr Res (2010) 1.50
Association of clinical symptoms and neurocognitive performance in bipolar disorder: a longitudinal study. Bipolar Disord (2011) 1.50
ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology (2006) 1.49
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol (2009) 1.49
Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol (2006) 1.47
The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS). Psychiatry Res (2007) 1.45
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol (2009) 1.44
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res (2010) 1.43
Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. J Clin Psychiatry (2016) 1.43
Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population. Am J Med (2012) 1.42
Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry (2009) 1.42
Social cognitive skills training in schizophrenia: an initial efficacy study of stabilized outpatients. Schizophr Res (2008) 1.41
Treatment noncompliance with orally disintegrating olanzapine tablets. Can J Psychiatry (2003) 1.39
Beyond capacity: identifying ethical dilemmas underlying capacity evaluation requests. Psychosomatics (2012) 1.39
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull (2008) 1.38
Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med (2009) 1.38
Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull (2011) 1.38
A randomized trial of depression assessment intervention in home health care. J Am Geriatr Soc (2007) 1.37
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull (2010) 1.36
Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry (2009) 1.35
Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry (2004) 1.33
Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry (2010) 1.33
Prevention of missing data in clinical research studies. Biol Psychiatry (2006) 1.32
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry (2007) 1.32
Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry (2008) 1.31
Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2013) 1.30
Further support for the role of dysfunctional attitudes in models of real-world functioning in schizophrenia. J Psychiatr Res (2009) 1.30
Social perception and early visual processing in schizophrenia. Schizophr Res (2003) 1.30
Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacol (2010) 1.29
Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res (2008) 1.29
Do the siblings of schizophrenia patients demonstrate affect perception deficits? Schizophr Res (2004) 1.27
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry (2011) 1.26
Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res (2006) 1.25
Statistical power and sample size requirements for three level hierarchical cluster randomized trials. Biometrics (2008) 1.25
A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry (2009) 1.24
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull (2003) 1.24
Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med (2007) 1.23
Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res (2008) 1.23